Mineralys Therapeutics, Inc. $MLYS Shares Sold by Capital International Investors

Capital International Investors trimmed its holdings in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 51.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,163,290 shares of the company’s stock after selling 1,230,106 shares during the period. Capital International Investors owned approximately 1.47% of Mineralys Therapeutics worth $42,216,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Hudson Bay Capital Management LP acquired a new position in Mineralys Therapeutics during the third quarter worth $2,873,000. SG Americas Securities LLC raised its position in Mineralys Therapeutics by 130.7% during the fourth quarter. SG Americas Securities LLC now owns 230,795 shares of the company’s stock worth $8,376,000 after acquiring an additional 130,758 shares during the period. Vanguard Group Inc. raised its position in Mineralys Therapeutics by 29.8% during the third quarter. Vanguard Group Inc. now owns 3,018,999 shares of the company’s stock worth $114,480,000 after acquiring an additional 692,550 shares during the period. Citigroup Inc. raised its position in Mineralys Therapeutics by 501.7% during the third quarter. Citigroup Inc. now owns 163,168 shares of the company’s stock worth $6,187,000 after acquiring an additional 136,050 shares during the period. Finally, Jennison Associates LLC raised its position in Mineralys Therapeutics by 234.4% during the fourth quarter. Jennison Associates LLC now owns 1,258,653 shares of the company’s stock worth $45,677,000 after acquiring an additional 882,307 shares during the period. 84.46% of the stock is currently owned by institutional investors and hedge funds.

Mineralys Therapeutics Stock Up 7.5%

Mineralys Therapeutics stock opened at $24.18 on Wednesday. Mineralys Therapeutics, Inc. has a 52-week low of $12.59 and a 52-week high of $47.65. The firm has a market capitalization of $1.99 billion, a price-to-earnings ratio of -11.80 and a beta of 0.57. The company has a fifty day simple moving average of $27.94 and a 200-day simple moving average of $30.91.

Mineralys Therapeutics (NASDAQ:MLYS) last released its earnings results on Wednesday, May 6th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.04. On average, research analysts anticipate that Mineralys Therapeutics, Inc. will post -2.3 EPS for the current fiscal year.

Insider Buying and Selling at Mineralys Therapeutics

In other Mineralys Therapeutics news, Director Ra Capital Management, L.P. bought 310,700 shares of the company’s stock in a transaction dated Friday, March 27th. The stock was acquired at an average price of $23.67 per share, with a total value of $7,354,269.00. Following the completion of the acquisition, the director directly owned 5,767,221 shares of the company’s stock, valued at $136,510,121.07. This represents a 5.69% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider David Malcom Rodman sold 14,056 shares of the company’s stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $28.58, for a total transaction of $401,720.48. Following the sale, the insider directly owned 63,443 shares of the company’s stock, valued at $1,813,200.94. The trade was a 18.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 160,120 shares of company stock worth $4,295,413 over the last three months. 18.94% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have weighed in on MLYS. Jefferies Financial Group restated a “hold” rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. Wall Street Zen cut shares of Mineralys Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Tuesday, April 21st. TD Cowen began coverage on shares of Mineralys Therapeutics in a research report on Monday, April 27th. They set a “buy” rating for the company. Finally, HC Wainwright restated a “buy” rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Mineralys Therapeutics has an average rating of “Moderate Buy” and an average price target of $49.33.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.